BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J Gastroenterol 2019; 25(11): 1307-1326 [PMID: 30918425 DOI: 10.3748/wjg.v25.i11.1307] [Cited by in CrossRef: 89] [Cited by in F6Publishing: 73] [Article Influence: 29.7] [Reference Citation Analysis]
Number Citing Articles
1 Fetzer DT, Rosado-Mendez IM, Wang M, Robbin ML, Ozturk A, Wear KA, Ormachea J, Stiles TA, Fowlkes JB, Hall TJ, Samir AE. Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization. Radiology 2022;:212808. [PMID: 36098640 DOI: 10.1148/radiol.212808] [Reference Citation Analysis]
2 Hu H, Han Y, Cao C, He Y. The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. J Transl Med 2022;20:398. [PMID: 36064712 DOI: 10.1186/s12967-022-03611-4] [Reference Citation Analysis]
3 Wang X, Li W, Fu J, Ni Y, Liu K, Liu F. Correlation between T-Lymphocyte Subsets, Regulatory T Cells, and Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-8. [DOI: 10.1155/2022/6250751] [Reference Citation Analysis]
4 Zhang M, Zhang Y, Jiao X, Lai L, Qian Y, Sun B, Yang W. Identification and validation of immune related core transcription factors GTF2I in NAFLD. PeerJ 2022;10:e13735. [DOI: 10.7717/peerj.13735] [Reference Citation Analysis]
5 Zeng Y, He H, An Z. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease. Dis Markers 2022;2022:1254014. [PMID: 35811662 DOI: 10.1155/2022/1254014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Xia J, Jin G, Hua Q, Cui S, Li J. Nomogram for Quantitatively Estimating the Risk of Fibrosis Progression in Type 2 Diabetic Patients With Nonalcoholic Fatty Liver Disease: A Pilot Study. Front Endocrinol 2022;13:917304. [DOI: 10.3389/fendo.2022.917304] [Reference Citation Analysis]
7 Kechagias S, Ekstedt M, Simonsson C, Nasr P. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones (Athens) 2022. [PMID: 35661987 DOI: 10.1007/s42000-022-00377-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Noureddin M, Ntanios F, Malhotra D, Hoover K, Emir B, McLeod E, Alkhouri N. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. Hepatol Commun 2022. [PMID: 35365931 DOI: 10.1002/hep4.1935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Guan Y, Xu Y, Su H, Sun X, Li Y, Wang T. Effect of serum vitamin D on metabolic associated fatty liver disease: a large population-based study. Scand J Gastroenterol 2022;:1-10. [PMID: 35170370 DOI: 10.1080/00365521.2022.2039284] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mikolasevic I, Domislovic V, Krznaric-zrnic I, Krznaric Z, Virovic-jukic L, Stojsavljevic S, Grgurevic I, Milic S, Vukoja I, Puz P, Aralica M, Hauser G. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. Medicina 2022;58:252. [DOI: 10.3390/medicina58020252] [Reference Citation Analysis]
11 Guo Y, Chen J, Liu N, Liu Z, Shi B, Sun H. Association of Circulating TXNIP Levels with Fatty Liver in Newly Diagnosed Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes 2022;15:225-33. [PMID: 35115798 DOI: 10.2147/DMSO.S349153] [Reference Citation Analysis]
12 Gong M, Su C, Fan M, Wang P, Cui B, Guo Z, Liang S, Yang L, Liu X, Dai L, Wang Z. Mechanism by which Eucommia ulmoides leaves Regulate Nonalcoholic fatty liver disease based on system pharmacology. J Ethnopharmacol 2022;282:114603. [PMID: 34496264 DOI: 10.1016/j.jep.2021.114603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Ma Y, Kan C, Qiu H, Liu Y, Hou N, Han F, Shi J, Sun X. Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease. Front Pharmacol 2021;12:793586. [PMID: 34992540 DOI: 10.3389/fphar.2021.793586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Peng J, Liu MM, Jin JL, Cao YX, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Xu RX, Li JJ. NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. Lipids Health Dis 2022;21:3. [PMID: 34996457 DOI: 10.1186/s12944-021-01610-w] [Reference Citation Analysis]
15 Moran Villota S. Prevalence of non alcoholic fatty liver disease and associated factors? Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100659] [Reference Citation Analysis]
16 Du X, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Front Endocrinol (Lausanne) 2021;12:777075. [PMID: 34950105 DOI: 10.3389/fendo.2021.777075] [Reference Citation Analysis]
17 Alsaqal S, Hockings P, Ahlström H, Gummesson A, Hedström A, Hulthe J, Johansson L, Niessen HG, Schoelch C, Schultheis C, Vessby J, Wanders A, Rorsman F, Ebeling Barbier C. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis. J Magn Reson Imaging 2021. [PMID: 34953171 DOI: 10.1002/jmri.28040] [Reference Citation Analysis]
18 Wang J, Su Z, Feng Y, Xi R, Liu J, Wang P. Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China. BMC Gastroenterol 2021;21:482. [PMID: 34923965 DOI: 10.1186/s12876-021-02072-1] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
19 Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab 2021;12:20420188211055557. [PMID: 34840719 DOI: 10.1177/20420188211055557] [Reference Citation Analysis]
20 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
21 Zhang J, Tan J, Wang M, Wang Y, Dong M, Ma X, Sun B, Liu S, Zhao Z, Chen L, Liu K, Xin Y, Zhuang L. Lipid-induced DRAM recruits STOM to lysosomes and induces LMP to promote exosome release from hepatocytes in NAFLD. Sci Adv 2021;7:eabh1541. [PMID: 34731006 DOI: 10.1126/sciadv.abh1541] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Di Mauro S, Scamporrino A, Filippello A, Di Pino A, Scicali R, Malaguarnera R, Purrello F, Piro S. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci 2021;22:11905. [PMID: 34769333 DOI: 10.3390/ijms222111905] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
23 Marciano S, Dirchwolf M, Torres MC, Allevato J, García Dans C, García B, Pollarsky F, Gaite L, Sirotinsky E, Rios B, Anselmo MN, Peche M, Hurtado E, Haddad L, Narvaez A, Mauro E, Martinez A, Bellizzi C, Ratusnu N, D'Amico C, Arora S, Gadano A. Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00103-1. [PMID: 34690105 DOI: 10.1016/j.rgmxen.2021.09.002] [Reference Citation Analysis]
24 Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease. Lipids Health Dis 2021;20:134. [PMID: 34629059 DOI: 10.1186/s12944-021-01561-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
25 Hang W, Shu H, Wen Z, Liu J, Jin Z, Shi Z, Chen C, Wang DW. N-Acetyl Cysteine Ameliorates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease and Intracellular Triglyceride Accumulation by Preserving Mitochondrial Function. Front Pharmacol 2021;12:636204. [PMID: 34588976 DOI: 10.3389/fphar.2021.636204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Kaya E, Bakir A, Kani HT, Demirtas CO, Keklikkiran C, Yilmaz Y. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gut Liver 2020;14:486-91. [PMID: 31530739 DOI: 10.5009/gnl19173] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
27 Alamri AS, Alhomrani M, Alsanie WF, Alghamdi AJ, Alghamdi ZM, Al-Subaie AA, Alharthi YA, Alqurashi HH, Asdaq SMB. Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of Taif, Saudi Arabia: A retrospective study. Saudi J Biol Sci 2021;28:4921-5. [PMID: 34466067 DOI: 10.1016/j.sjbs.2021.05.063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Zhang R, Wang M, Wang M, Zhang L, Ding Y, Tang Z, Fu Z, Fan H, Zhang W, Wang J. Vitamin D Level and Vitamin D Receptor Genetic Variation Were Involved in the Risk of Non-Alcoholic Fatty Liver Disease: A Case-Control Study. Front Endocrinol (Lausanne) 2021;12:648844. [PMID: 34421816 DOI: 10.3389/fendo.2021.648844] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Liu G, Wu D, Wen Y, Cang S. Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma: an integrated analysis of GEO datasets. Bioengineered 2021;12:5253-65. [PMID: 34424809 DOI: 10.1080/21655979.2021.1962147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Pereira ENGDS, Paula DP, Araujo BP, Fonseca MJMD, Diniz MFHS, Daliry A, Griep RH. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol 2021; 27(29): 4913-4928 [PMID: 34447235 DOI: 10.3748/wjg.v27.i29.4913] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Chen CC, Hsu WC, Wu HM, Wang JY, Yang PY, Lin IC. Association between the Severity of Nonalcoholic Fatty Liver Disease and the Risk of Coronary Artery Calcification. Medicina (Kaunas) 2021;57:807. [PMID: 34441013 DOI: 10.3390/medicina57080807] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chou TH, Yeh HJ, Chang CC, Tang JH, Kao WY, Su IC, Li CH, Chang WH, Huang CK, Sufriyana H, Su EC. Deep learning for abdominal ultrasound: A computer-aided diagnostic system for the severity of fatty liver. J Chin Med Assoc 2021. [PMID: 34282076 DOI: 10.1097/JCMA.0000000000000585] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
33 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
34 Akhavan Rezayat A, Ghasemi Nour M, Bondarsahebi Y, Hozhabrossadati SA, Amirkhanlou F, Akhavan Rezayat S, Kiani M, Imani B. The effects of melatonin therapy on the treatment of patients with Non-alcoholic steatohepatitis: A systematic review and Meta-analysis on clinical trial studies. Eur J Pharmacol 2021;905:174154. [PMID: 34058202 DOI: 10.1016/j.ejphar.2021.174154] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
35 Hari A. Ultrasound Elastography-Cornerstone of Non-Invasive Metabolic Dysfunction-Associated Fatty Liver Disease Assessment. Medicina (Kaunas) 2021;57:516. [PMID: 34064124 DOI: 10.3390/medicina57060516] [Reference Citation Analysis]
36 Kuroda H, Fujiwara Y, Abe T, Nagasawa T, Oguri T, Noguchi S, Kamiyama N, Takikawa Y. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis. PLoS One 2021;16:e0249493. [PMID: 33826669 DOI: 10.1371/journal.pone.0249493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Di Stasi V, Maseroli E, Rastrelli G, Scavello I, Cipriani S, Todisco T, Marchiani S, Sorbi F, Fambrini M, Petraglia F, Maggi M, Vignozzi L. SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirsutism and in Women With Sexual Dysfunction. Front Endocrinol (Lausanne). 2021;12:641446. [PMID: 33854482 DOI: 10.3389/fendo.2021.641446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Marciano S, Dirchwolf M, Torres MC, Allevato J, García Dans C, García B, Pollarsky F, Gaite L, Sirotinsky E, Rios B, Anselmo MN, Peche M, Hurtado E, Haddad L, Narvaez A, Mauro E, Martinez A, Bellizzi C, Ratusnu N, D Amico C, Arora S, Gadano A. Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them. Rev Gastroenterol Mex (Engl Ed) 2021:S0375-0906(21)00015-X. [PMID: 33773856 DOI: 10.1016/j.rgmx.2020.08.006] [Reference Citation Analysis]
39 Zhang J, Li K, Pan L, Teng F, Zhang P, Lin B, Yuan Y, Wei X, Li W, Zhang H. Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study. BMC Gastroenterol 2021;21:131. [PMID: 33743586 DOI: 10.1186/s12876-021-01721-9] [Reference Citation Analysis]
40 Huang P, Tu B, Liao HJ, Huang FZ, Li ZZ, Zhu KY, Dai F, Liu HZ, Zhang TY, Sun CZ. Elevation of plasma tRNA fragments as a promising biomarker for liver fibrosis in nonalcoholic fatty liver disease. Sci Rep 2021;11:5886. [PMID: 33723340 DOI: 10.1038/s41598-021-85421-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
41 Yin XZ, Chi WM, Zhang L, Su YQ, Zhang ZY, Xue CB. Protective effects of Dendrobium candidum Wall ex Lindl. on high-fat diet-induced liver damage in mice. J Food Biochem 2021;45:e13687. [PMID: 33665859 DOI: 10.1111/jfbc.13687] [Reference Citation Analysis]
42 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
43 Jeon SK, Lee JM, Joo I. Clinical Feasibility of Quantitative Ultrasound Imaging for Suspected Hepatic Steatosis: Intra- and Inter-examiner Reliability and Correlation with Controlled Attenuation Parameter. Ultrasound in Medicine & Biology 2021;47:438-45. [DOI: 10.1016/j.ultrasmedbio.2020.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
44 Zhang L, She ZG, Li H, Zhang XJ. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. Clin Sci (Lond) 2020;134:1775-99. [PMID: 32677680 DOI: 10.1042/CS20200446] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
45 Chin KM, Prieto M, Cheong CK, Di Martino M, Ielpo B, Goh BKP, Koh YX. Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature. HPB (Oxford) 2021;23:1164-74. [PMID: 33608215 DOI: 10.1016/j.hpb.2021.01.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Perez-Diaz-Del-Campo N, Marin-Alejandre BA, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Riezu-Boj JI, Milagro FI, Tur JA, Martinez JA, Abete I, Zulet MA. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study. Eur J Nutr 2021;60:3043-57. [PMID: 33474638 DOI: 10.1007/s00394-020-02476-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Andersen G, Plum-Mörschel L, Hockings PD, Morsing A, Palle MS, Svolgaard O, Flint A. Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data. Adv Ther 2020;37:4866-76. [PMID: 33006125 DOI: 10.1007/s12325-020-01503-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Bayrak M. Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors. Aging Male 2020;23:1275-82. [PMID: 32396414 DOI: 10.1080/13685538.2020.1763293] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
49 Morze J, Koch M, Aroner SA, Budoff M, McClelland RL, Mukamal KJ, Jensen MK. Associations of HDL Subspecies Defined by ApoC3 with Non-Alcoholic Fatty Liver Disease: The Multi-Ethnic Study of Atherosclerosis. J Clin Med 2020;9:E3522. [PMID: 33142714 DOI: 10.3390/jcm9113522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Bullón-Vela V, Abete I, Tur JA, Konieczna J, Romaguera D, Pintó X, Corbella E, Martínez-González MA, Sayón-Orea C, Toledo E, Corella D, Macías-Gonzalez M, Tinahones FJ, Fitó M, Estruch R, Ros E, Salas-Salvadó J, Daimiel L, Mascaró CM, Zulet MA, Martínez JA. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. Ther Adv Endocrinol Metab 2020;11:2042018820958298. [PMID: 33149882 DOI: 10.1177/2042018820958298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
52 Mosca A, Panera N, Crudele A, Alisi A. Noninvasive diagnostic tools for pediatric NAFLD: where are we now? Expert Review of Gastroenterology & Hepatology 2020;14:1035-46. [DOI: 10.1080/17474124.2020.1801413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
53 Zhang Z, Thorne JL, Moore JB. Vitamin D and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2019;22:449-58. [PMID: 31589177 DOI: 10.1097/MCO.0000000000000605] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
54 Chen YY, Yeh MM. Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. J Formos Med Assoc 2021;120:68-77. [PMID: 32654868 DOI: 10.1016/j.jfma.2020.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
55 Lee DH. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2020;35:243-59. [PMID: 32615709 DOI: 10.3803/EnM.2020.35.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
56 Pervez MA, Khan DA, Slehria AUR, Ijaz A. Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial. Complement Ther Med 2020;52:102494. [PMID: 32951743 DOI: 10.1016/j.ctim.2020.102494] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
57 Abd El-Wahab EW, Zein El-Abedin RA, Ahmed WM, Shatat HZ. Validation of a Non-Laboratory Based Screening Tool for Predicting Non-Alcoholic Fatty Liver Disease in an Egyptian Setting. Am J Med Sci 2020;360:662-77. [PMID: 32739036 DOI: 10.1016/j.amjms.2020.06.020] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
58 Li J, Venkatesh SK, Yin M. Advances in Magnetic Resonance Elastography of Liver. Magn Reson Imaging Clin N Am 2020;28:331-40. [PMID: 32624152 DOI: 10.1016/j.mric.2020.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
59 Sun HJ, Wu ZY, Nie XW, Wang XY, Bian JS. Implications of hydrogen sulfide in liver pathophysiology: Mechanistic insights and therapeutic potential. J Adv Res 2021;27:127-35. [PMID: 33318872 DOI: 10.1016/j.jare.2020.05.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
60 Eguchi Y, Wong G, Akhtar O, Sumida Y. Non‐invasive diagnosis of non‐alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review. Hepatol Res 2020;50:645-55. [DOI: 10.1111/hepr.13502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
61 Gao F, Huang JF, Zheng KI, Pan XY, Ma HL, Liu WY, Byrne CD, Targher G, Li YY, Chen YP, Chan WK, Zheng MH. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:1804-12. [PMID: 32246876 DOI: 10.1111/jgh.15055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
62 Maciejewska D, Drozd A, Skonieczna-Żydecka K, Skórka-Majewicz M, Dec K, Jakubczyk K, Pilutin A, Stachowska E. Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression? Molecules 2020;25:E2026. [PMID: 32349225 DOI: 10.3390/molecules25092026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
63 Wang Y, Zeng Z, Guan L, Ao R. GRHL2 induces liver fibrosis and intestinal mucosal barrier dysfunction in non-alcoholic fatty liver disease via microRNA-200 and the MAPK pathway. J Cell Mol Med 2020;24:6107-19. [PMID: 32324317 DOI: 10.1111/jcmm.15212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
64 Alsaif FA, Alqahtani SH, Alsadoon AM, Alswat KA, Abdo AA, Hassanain MM, Alsharabi AB, Aljuhani GR, Alkhalidi HM, Elsharkawy MS, Alotaibi MA, Sanai FM, Al-Hamoudi WK. Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease. Saudi J Gastroenterol. 2020;. [PMID: 32341228 DOI: 10.4103/sjg.sjg_29_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Liu X, Chen S, Zhang L. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 2020;319:E34-42. [PMID: 32228319 DOI: 10.1152/ajpendo.00528.2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
66 Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 2020;152:116-41. [PMID: 32156524 DOI: 10.1016/j.freeradbiomed.2020.02.025] [Cited by in Crossref: 90] [Cited by in F6Publishing: 208] [Article Influence: 45.0] [Reference Citation Analysis]
67 Zhao Y, Zhao G, Chen Z, She Z, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension 2020;75:275-84. [DOI: 10.1161/hypertensionaha.119.13419] [Cited by in Crossref: 21] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
68 Ocker M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. Eur J Pharmacol 2020;870:172913. [PMID: 31926994 DOI: 10.1016/j.ejphar.2020.172913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
69 Wahlang B, Appana S, Falkner KC, McClain CJ, Brock G, Cave MC. Insecticide and metal exposures are associated with a surrogate biomarker for non-alcoholic fatty liver disease in the National Health and Nutrition Examination Survey 2003-2004. Environ Sci Pollut Res Int 2020;27:6476-87. [PMID: 31873887 DOI: 10.1007/s11356-019-07066-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
70 Recaredo G, Marin-Alejandre BA, Cantero I, Monreal JI, Herrero JI, Benito-Boillos A, Elorz M, Tur JA, Martínez JA, Zulet MA, Abete I. Association between Different Animal Protein Sources and Liver Status in Obese Subjects with Non-Alcoholic Fatty Liver Disease: Fatty Liver in Obesity (FLiO) Study. Nutrients 2019;11:E2359. [PMID: 31623368 DOI: 10.3390/nu11102359] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
71 Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
72 Miles DA, Levi CS, Uhanova J, Cuvelier S, Hawkins K, Minuk GY. Pocket-Sized Versus Conventional Ultrasound for Detecting Fatty Infiltration of the Liver. Dig Dis Sci 2020;65:82-5. [DOI: 10.1007/s10620-019-05752-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
73 Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. Int J Mol Sci. 2019;20. [PMID: 31212642 DOI: 10.3390/ijms20112841] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 15.3] [Reference Citation Analysis]